FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034303217> ?p ?o ?g. }

• W2034303217 endingPage "191" @default.
• W2034303217 startingPage "182" @default.
• W2034303217 abstract "Human aldo-keto reductases (AKR) of the 1A, 1B, 1C and 1D subfamilies are involved in the pre-receptor regulation of nuclear (steroid hormone and orphan) receptors by regulating the local concentrations of their lipophilic ligands. AKR1C3 is one of the most interesting isoforms. It was cloned from human prostate and the recombinant protein was found to function as a 3-, 17- and 20-ketosteroid reductase with a preference for the conversion of Δ4-androstene-3,17-dione to testosterone implicating this enzyme in the local production of active androgens within the prostate. Using a validated isoform specific real-time RT-PCR procedure the AKR1C3 transcript was shown to be more abundant in primary cultures of epithelial cells than stromal cells, and its expression in stromal cells increased with benign and malignant disease. Using a validated isoform specific monoclonal Ab, AKR1C3 protein expression was also detected in prostate epithelial cells by immunoblot analysis. Immunohistochemical staining of prostate tissue showed that AKR1C3 was expressed in adenocarcinoma and surprisingly high expression was observed in the endothelial cells. These cells are a rich source of prostaglandin G/H synthase 2 (COX-2) and vasoactive prostaglandins (PG) and thus the ability of recombinant AKR1C enzymes to act as PGF synthases was compared. AKR1C3 had the highest catalytic efficiency (kcat/Km) for the 11-ketoreduction of PGD2 to yield 9α,11β-PGF2 raising the prospect that AKR1C3 may govern ligand access to peroxisome proliferator activated receptor (PPARγ). Activation of PPARγ is often a pro-apoptotic signal and/or leads to terminal differentiation, while 9α,11β-PGF2 is a pro-proliferative signal. AKR1C3 is potently inhibited by non-steroidal anti-inflammatory drugs suggesting that the cancer chemopreventive properties of these agents may be mediated either by inhibition of AKR1C3 or COX. To discriminate between these effects we developed potent AKR1C inhibitors based on N-phenylanthranilic acids that do not inhibit COX-1 or COX-2. These compounds can now be used to determine the role of AKR1C3 in producing two proliferative signals in the prostate namely testosterone and 9α,11β-PGF2." @default.
• W2034303217 created "2016-06-24" @default.
• W2034303217 creator A5008562682 @default.
• W2034303217 creator A5015375011 @default.
• W2034303217 creator A5019174025 @default.
• W2034303217 creator A5026491149 @default.
• W2034303217 creator A5030032300 @default.
• W2034303217 creator A5047721884 @default.
• W2034303217 creator A5059737908 @default.
• W2034303217 creator A5076664506 @default.
• W2034303217 date "2006-03-01" @default.
• W2034303217 modified "2023-10-16" @default.
• W2034303217 title "Aldo-keto reductase (AKR) 1C3: Role in prostate disease and the development of specific inhibitors" @default.
• W2034303217 cites W1966209935 @default.
• W2034303217 cites W1972979082 @default.
• W2034303217 cites W1978660247 @default.
• W2034303217 cites W1984253132 @default.
• W2034303217 cites W1990051527 @default.
• W2034303217 cites W2001657099 @default.
• W2034303217 cites W2011478728 @default.
• W2034303217 cites W2023007598 @default.
• W2034303217 cites W2026352933 @default.
• W2034303217 cites W2028466456 @default.
• W2034303217 cites W2032925662 @default.
• W2034303217 cites W2054535723 @default.
• W2034303217 cites W2056020627 @default.
• W2034303217 cites W2062949189 @default.
• W2034303217 cites W2066518128 @default.
• W2034303217 cites W2068470211 @default.
• W2034303217 cites W2071373198 @default.
• W2034303217 cites W2073994722 @default.
• W2034303217 cites W2083470544 @default.
• W2034303217 cites W2084582367 @default.
• W2034303217 cites W2091149475 @default.
• W2034303217 cites W2101605468 @default.
• W2034303217 cites W2105884586 @default.
• W2034303217 cites W2114756989 @default.
• W2034303217 cites W2125072209 @default.
• W2034303217 cites W2126243275 @default.
• W2034303217 cites W2127560071 @default.
• W2034303217 cites W2130690545 @default.
• W2034303217 cites W2138873293 @default.
• W2034303217 cites W2158087731 @default.
• W2034303217 cites W2158795471 @default.
• W2034303217 cites W2162536302 @default.
• W2034303217 cites W2164373167 @default.
• W2034303217 cites W4205877643 @default.
• W2034303217 doi "https://doi.org/10.1016/j.mce.2005.12.009" @default.
• W2034303217 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16417966" @default.
• W2034303217 hasPublicationYear "2006" @default.
• W2034303217 type Work @default.
• W2034303217 sameAs 2034303217 @default.
• W2034303217 citedByCount "106" @default.
• W2034303217 countsByYear W20343032172012 @default.
• W2034303217 countsByYear W20343032172013 @default.
• W2034303217 countsByYear W20343032172014 @default.
• W2034303217 countsByYear W20343032172015 @default.
• W2034303217 countsByYear W20343032172016 @default.
• W2034303217 countsByYear W20343032172017 @default.
• W2034303217 countsByYear W20343032172018 @default.
• W2034303217 countsByYear W20343032172019 @default.
• W2034303217 countsByYear W20343032172020 @default.
• W2034303217 countsByYear W20343032172021 @default.
• W2034303217 countsByYear W20343032172022 @default.
• W2034303217 countsByYear W20343032172023 @default.
• W2034303217 crossrefType "journal-article" @default.
• W2034303217 hasAuthorship W2034303217A5008562682 @default.
• W2034303217 hasAuthorship W2034303217A5015375011 @default.
• W2034303217 hasAuthorship W2034303217A5019174025 @default.
• W2034303217 hasAuthorship W2034303217A5026491149 @default.
• W2034303217 hasAuthorship W2034303217A5030032300 @default.
• W2034303217 hasAuthorship W2034303217A5047721884 @default.
• W2034303217 hasAuthorship W2034303217A5059737908 @default.
• W2034303217 hasAuthorship W2034303217A5076664506 @default.
• W2034303217 hasConcept C104317684 @default.
• W2034303217 hasConcept C134018914 @default.
• W2034303217 hasConcept C134651460 @default.
• W2034303217 hasConcept C153911025 @default.
• W2034303217 hasConcept C16930146 @default.
• W2034303217 hasConcept C170493617 @default.
• W2034303217 hasConcept C181199279 @default.
• W2034303217 hasConcept C2777486698 @default.
• W2034303217 hasConcept C502942594 @default.
• W2034303217 hasConcept C53345823 @default.
• W2034303217 hasConcept C55493867 @default.
• W2034303217 hasConcept C63932345 @default.
• W2034303217 hasConcept C86339819 @default.
• W2034303217 hasConcept C86803240 @default.
• W2034303217 hasConceptScore W2034303217C104317684 @default.
• W2034303217 hasConceptScore W2034303217C134018914 @default.
• W2034303217 hasConceptScore W2034303217C134651460 @default.
• W2034303217 hasConceptScore W2034303217C153911025 @default.
• W2034303217 hasConceptScore W2034303217C16930146 @default.
• W2034303217 hasConceptScore W2034303217C170493617 @default.
• W2034303217 hasConceptScore W2034303217C181199279 @default.
• W2034303217 hasConceptScore W2034303217C2777486698 @default.
• W2034303217 hasConceptScore W2034303217C502942594 @default.
• W2034303217 hasConceptScore W2034303217C53345823 @default.

• next